| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a clinical-stage biotechnology company that develops therapeutics designed to harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Headquartered in Paris, Fra..
>Volltext.. |
| 6815.2 Mio. EUR |
| 6414.57 Mio. EUR |
| - |
| -301.51 Mio. EUR |
| -408.08 Mio. EUR |
| -5.32 EUR |
| 1.23 Mio. EUR |
| 394.63 Mio. EUR |
| -197.04 Mio. EUR |
| 5.61 |
| - |
| -126.13% |
| - |
| - |
| - |
| - |
| ABIVAX |
| 22.10.26 |
|